Truist analyst David MacDonald lowered the firm’s price target on HCA Healthcare (HCA) to $390 from $430 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 for Healthcare Services. The firm sees the outlook for the group as “mixed”, with bullish stance on the underlying demand drivers and overarching sector tailwinds that include demographics, value-based care, and core demand being offset by heightened concern around a likely more cost focused government backdrop. Selectivity is key and cash flow generation with broadly attractive financial flexibility are set to provide solid support, while the recent valuation re-rating for several names provides a better setup around risk/reward, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare chief ethics, compliance officer Kathi Whalen to retire
- HCA Healthcare price target lowered to $355 from $406 at Morgan Stanley
- HCA Healthcare assumed with a Neutral at JPMorgan
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Block, Five Below downgraded: Wall Street’s top analyst calls